Navigation Links
Tris Pharma Announces US Patent Grant Covering Platform Technology
Date:1/6/2012

MONMOUTH JUNCTION, N.J., Jan. 6, 2012 /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+™ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes. 

"This patent grant further validates Tris' breakthrough in commercializing modified release formulation involving unique dosage forms such as a 24-hour ER liquid suspension.  The patent covers our unique, high tensile, aqueous coating compositions and combined with our patent-pending/trade-secret manufacturing process and special design apparatus provides for an efficient and scalable manufacturing capabilities. This has resulted in launch of several new, first-in-the-category products that were heretofore not capable of being developed," said Ketan Mehta, President and CEO of Tris Pharma.

While the benefits of modified release are well understood, these benefits were largely limited to patients who can swallow traditional solid dosage forms.  The OralXR+ technology bridges the gap for patients who have difficulty swallowing "pills" and thereby helps extend the market for modified release products. Tris is working with multiple pharma partners to develop products based on this patented technology in the areas of CNS, respiratory, pain, cardiovascular, and OTC cough/cold.

About Tris Pharma
Tris Pharma is an emerging specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine
2. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
3. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
4. ViroPharma Provides 2012 Outlook
5. Pharmaceutical Workers Elect Union Representation
6. Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor
7. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
8. Parata Systems Announces Presenting Sponsorship of 2012 Independent Pharmacy Business Growth Conference
9. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
10. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
11. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to ... ... Volume, Company Analysis and Forecast to 2022 provides a comprehensive ... The growing prevalence of hearing impairment coupled with an expanding ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, ... has announced the launch of an opioid management ... guidelines on opioids and helps stem the growing ... often prescribed to treat chronic non-cancer pain (back ... serious risks and lack of evidence regarding long-term ...
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... ... enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is the ... devoted woman of faith. , “Becoming a parent changes you. In my case, the ... years, but actually doing it might have been a while in coming if it hadn’t ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):